Patents by Inventor Christel Bonnas

Christel Bonnas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190106470
    Abstract: The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.
    Type: Application
    Filed: June 4, 2018
    Publication date: April 11, 2019
    Applicant: CHARITE UNIVERSITAETSMEDIZEN-BERLIN
    Inventors: Andreas MEISEL, Josef PRILLER, Christel BONNAS, Ulrich DIRNAGL
  • Patent number: 9988427
    Abstract: The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 5, 2018
    Assignee: CHARITE UNIVERSITAETSMEDIZEN-BERLIN
    Inventors: Andreas Meisel, Josef Priller, Christel Bonnas, Ulrich Dirnagl
  • Patent number: 8895303
    Abstract: In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or progenitor cells, wherein the media comprises a vEPO protein variant, (iii) purifying the stem or progenitor cells ex vivo. The invention relates to a method of increasing the number and survival of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. The invention also relates to improved differentiation of stem and progenitor cells in vitro and in vivo using a vEPO protein variant.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: November 25, 2014
    Assignee: Charite-Universitatsmedizin Berlin
    Inventors: Josef Priller, Christel Bonnas, Andreas Meisel
  • Publication number: 20110300114
    Abstract: In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or progenitor cells, wherein the media comprises a vEPO protein variant, (iii) purifying the stem or progenitor cells ex vivo. The invention relates to a method of increasing the number and survival of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. The invention also relates to improved differentiation of stem and progenitor cells in vitro and in vivo using a vEPO protein variant.
    Type: Application
    Filed: November 12, 2007
    Publication date: December 8, 2011
    Applicant: VOSSIUS & PARTNER
    Inventors: Josef Priller, Christel Bonnas, Andreas Meisel
  • Publication number: 20110008363
    Abstract: The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.
    Type: Application
    Filed: December 15, 2008
    Publication date: January 13, 2011
    Inventors: Andreas Meisel, Josef Priller, Christel Bonnas, Ulrich Dirnagl